Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 35

1.

Systematic Review of Intravenous Ascorbate in Cancer Clinical Trials.

Nauman G, Gray JC, Parkinson R, Levine M, Paller CJ.

Antioxidants (Basel). 2018 Jul 12;7(7). pii: E89. doi: 10.3390/antiox7070089. Review.

2.

Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.

Teply BA, Wang H, Luber B, Sullivan R, Rifkind I, Bruns A, Spitz A, DeCarli M, Sinibaldi V, Pratz CF, Lu C, Silberstein JL, Luo J, Schweizer MT, Drake CG, Carducci MA, Paller CJ, Antonarakis ES, Eisenberger MA, Denmeade SR.

Lancet Oncol. 2018 Jan;19(1):76-86. doi: 10.1016/S1470-2045(17)30906-3. Epub 2017 Dec 14.

3.

State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research-NCI Strategic Workshop Highlights of Discussion Report.

Xi D, Bao T, Chen Q, Chen S, Cheng YC, Cullen J, Frank DA, Friedberg JW, Kronish I, Lee JE, Levine M, Li P, Li S, Lu W, Mao JJ, O'Keefe S, Rubinstein L, Shah MA, Standish L, Paller CJ, Chu E.

J Natl Cancer Inst Monogr. 2017 Nov 1;2017(52). doi: 10.1093/jncimonographs/lgx003.

PMID:
29140484
4.

Muscadine Grape Skin Extract (MPX) in Men with Biochemically Recurrent Prostate Cancer: A Randomized, Multicenter, Placebo-Controlled Clinical Trial.

Paller CJ, Zhou XC, Heath EI, Taplin ME, Mayer T, Stein MN, Bubley GJ, Pili R, Hudson T, Kakarla R, Abbas MM, Anders NM, Dowling D, King S, Bruns AB, Wagner WD, Drake CG, Antonarakis ES, Eisenberger MA, Denmeade SR, Rudek MA, Rosner GL, Carducci MA.

Clin Cancer Res. 2018 Jan 15;24(2):306-315. doi: 10.1158/1078-0432.CCR-17-1100. Epub 2017 Nov 7.

PMID:
29113986
5.

Risk factors for metastatic prostate cancer: A sentinel event case series.

Paller CJ, Cole AP, Partin AW, Carducci MA, Kanarek NF.

Prostate. 2017 May;77(13):1366-1372. doi: 10.1002/pros.23396. Epub 2017 Aug 8.

6.

A review of pomegranate in prostate cancer.

Paller CJ, Pantuck A, Carducci MA.

Prostate Cancer Prostatic Dis. 2017 Sep;20(3):265-270. doi: 10.1038/pcan.2017.19. Epub 2017 Apr 25. Review.

7.

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Zhu Y, Silberstein JL, Taylor MN, Maughan BL, Denmeade SR, Pienta KJ, Paller CJ, Carducci MA, Eisenberger MA, Luo J.

J Clin Oncol. 2017 Jul 1;35(19):2149-2156. doi: 10.1200/JCO.2016.70.1961. Epub 2017 Apr 6.

8.

Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report.

Markowski MC, Imus P, Wright JL, Schottenstein D, Paller CJ.

Clin Genitourin Cancer. 2017 Oct;15(5):e839-e842. doi: 10.1016/j.clgc.2017.02.001. Epub 2017 Feb 27. No abstract available.

9.

Detection fidelity of AR mutations in plasma derived cell-free DNA.

Goldstein A, Toro PV, Lee J, Silberstein JL, Nakazawa M, Waters I, Cravero K, Chu D, Cochran RL, Kim M, Shinn D, Torquato S, Hughes RM, Pallavajjala A, Carducci MA, Paller CJ, Denmeade SR, Kressel B, Trock BJ, Eisenberger MA, Antonarakis ES, Park BH, Hurley PJ.

Oncotarget. 2017 Feb 28;8(9):15651-15662. doi: 10.18632/oncotarget.14926.

10.

Challenges of conducting clinical trials of natural products to combat cancer.

Paller CJ, Denmeade SR, Carducci MA.

Clin Adv Hematol Oncol. 2016 Jun;14(6):447-55. Review.

PMID:
27379814
11.

Circulating Tumor DNA as a Marker of Therapeutic Response in Patients With Renal Cell Carcinoma: A Pilot Study.

Ball MW, Gorin MA, Guner G, Pierorazio PM, Netto G, Paller CJ, Hammers HJ, Diaz LA, Allaf ME.

Clin Genitourin Cancer. 2016 Oct;14(5):e515-e520. doi: 10.1016/j.clgc.2016.03.019. Epub 2016 Mar 24. No abstract available.

12.

Phytotherapeutic interventions in the management of biochemically recurrent prostate cancer: a systematic review of randomised trials.

van Die MD, Bone KM, Emery J, Williams SG, Pirotta MV, Paller CJ.

BJU Int. 2016 Apr;117 Suppl 4:17-34. doi: 10.1111/bju.13361. Epub 2016 Feb 22. Review.

13.

Prognostic factors for clinical outcomes in patients with metastatic castration resistant prostate cancer treated with sequential novel androgen receptor-directed therapies.

Nadal R, Tsai HL, Sinibaldi VJ, Paller CJ, Antonarakis ES, Denmeade SR, Carducci MA, Eisenberger MA.

Prostate. 2016 Apr;76(5):512-20. doi: 10.1002/pros.23141. Epub 2015 Dec 22.

PMID:
26689606
14.

Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

JAMA Oncol. 2015 Aug;1(5):582-91. doi: 10.1001/jamaoncol.2015.1341.

15.

Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital.

Markowski MC, Eisenberger MA, Zahurak M, Epstein JI, Paller CJ.

Urology. 2015 Sep;86(3):539-43. doi: 10.1016/j.urology.2015.06.011. Epub 2015 Jun 28.

16.

Serial blood-based analysis of AR-V7 in men with advanced prostate cancer.

Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES.

Ann Oncol. 2015 Sep;26(9):1859-65. doi: 10.1093/annonc/mdv282. Epub 2015 Jun 27.

17.

Risk of prostate cancer in African-American men: Evidence of mixed effects of dietary quercetin by serum vitamin D status.

Paller CJ, Kanaan YM, Beyene DA, Naab TJ, Copeland RL, Tsai HL, Kanarek NF, Hudson TS.

Prostate. 2015 Sep;75(13):1376-83. doi: 10.1002/pros.23018. Epub 2015 Jun 5.

18.

A phase I study of muscadine grape skin extract in men with biochemically recurrent prostate cancer: Safety, tolerability, and dose determination.

Paller CJ, Rudek MA, Zhou XC, Wagner WD, Hudson TS, Anders N, Hammers HJ, Dowling D, King S, Antonarakis ES, Drake CG, Eisenberger MA, Denmeade SR, Rosner GL, Carducci MA.

Prostate. 2015 Oct;75(14):1518-25. doi: 10.1002/pros.23024. Epub 2015 May 27.

19.

AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.

Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

N Engl J Med. 2014 Sep 11;371(11):1028-38. doi: 10.1056/NEJMoa1315815. Epub 2014 Sep 3.

20.

Clinical activity of enzalutamide in Docetaxel-naïve and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer.

Nadal R, Zhang Z, Rahman H, Schweizer MT, Denmeade SR, Paller CJ, Carducci MA, Eisenberger MA, Antonarakis ES.

Prostate. 2014 Nov;74(15):1560-8. doi: 10.1002/pros.22874. Epub 2014 Aug 31.

Supplemental Content

Loading ...
Support Center